Form 4: Metsera CMO Converts Equity Post-Pfizer Merger

Metsera's Chief Medical Officer, Steven Marso, disposed of all common stock, restricted stock units, and stock options following the company's acquisition by Pfizer Inc. for $65.60 per share plus contingent value rights.

Summary

• Metsera, Inc. completed its merger with Mayfair Merger Sub, Inc., a wholly-owned subsidiary of Pfizer Inc., on November 13, 2025, with Metsera continuing as a wholly-owned subsidiary of Pfizer Inc.
• At the effective time of the merger, each outstanding share of Metsera common stock was converted into the right to receive $65.60 in cash (the 'Closing Amount') and one contractual contingent value right (CVR) for potential future payments.
• Steven Marso, Metsera's Chief Medical Officer, disposed of 17,000 shares of common stock as a result of the merger.
• Marso's 17,000 restricted stock units (RSUs), granted on November 12, 2025, were cancelled and converted into cash equal to the Closing Amount multiplied by the number of shares underlying the RSUs, plus a corresponding number of CVRs. These cash payments and CVRs are subject to the original RSU vesting schedule.
• Marso's stock options, totaling 971,164 shares across three grants (120,000 at $29.25, 829,885 at $0.26, and 21,279 at $0.26), were cancelled.
• Cancelled stock options were exchanged for cash equal to the product of (i) the excess of the Closing Amount over the option's exercise price, multiplied by (ii) the number of shares subject to the option, plus one CVR for each share underlying the option.
• For unvested stock options, the cash payment and CVRs are subject to the original vesting schedule, with full vesting upon the first anniversary of the merger's closing, contingent on continued service with Pfizer or its subsidiaries.

Sentiment

Score: 8

Explanation: The filing details the successful completion of a merger, resulting in a significant cash payout and potential future contingent value rights for shareholders and the reporting person. This represents a positive liquidity event and a successful outcome for the company's equity holders.

Positives

• Metsera shareholders, including the reporting person, received a significant cash payout of $65.60 per share for their common stock.
• The inclusion of Contingent Value Rights (CVRs) provides an opportunity for additional future payments based on the achievement of specified milestones, offering potential upside beyond the initial cash consideration.
• The acquisition by Pfizer Inc. provides a clear exit strategy for Metsera and its investors, integrating its assets into a major pharmaceutical company.

Negatives

• Metsera, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Pfizer Inc.
• The value of the CVRs is contingent on future events and milestones, meaning there is no guarantee of additional payments beyond the initial cash consideration.
• Unvested stock options and RSUs converted into cash and CVRs remain subject to vesting schedules and continued service, tying the reporting person's future compensation to employment with Pfizer.

Risks

• The Contingent Value Rights (CVRs) are contractual rights to receive payments only upon the achievement of certain specified milestones, which may not occur, leading to no additional payments.
• The cash payments and CVRs for unvested stock options and RSUs are subject to continued service with Pfizer or its subsidiaries, posing a risk if employment is terminated before vesting is complete.

Future Outlook

Metsera, Inc. is now a wholly-owned subsidiary of Pfizer Inc. Future payments related to the Contingent Value Rights (CVRs) are possible upon the achievement of specified milestones. For the reporting person, cash payments and CVRs from unvested equity awards will vest upon continued service with Pfizer or its subsidiaries through the first anniversary of the merger.

Management Comments

• The merger agreement specifies that each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for cash and CVRs.
• Unvested stock options and RSUs converted into cash payments and CVRs are subject to the same vesting schedule terms as originally applicable, with full vesting upon the first anniversary of the merger's closing, subject to continued service.

Industry Context

This transaction reflects a common trend in the pharmaceutical and biotechnology industry where larger established companies like Pfizer acquire smaller, innovative firms like Metsera to expand their pipeline and intellectual property. The use of CVRs is a typical mechanism to bridge valuation gaps and share future development risks and rewards in such acquisitions.

Comparison to Industry Standards

• The merger structure, involving an upfront cash payment combined with Contingent Value Rights (CVRs), is a standard approach in biotech acquisitions. This allows the acquirer (Pfizer) to mitigate risk by tying a portion of the consideration to the successful achievement of future development or regulatory milestones, while providing the target's shareholders (Metsera) with potential upside.
• The conversion of employee equity awards (stock options, RSUs) into cash and CVRs, with continued service requirements for unvested portions, is also a common practice designed to retain key personnel post-acquisition and align their incentives with the success of the acquired assets under the new parent company.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $65.60 cash per share and one CVR per share, representing a significant return on investment and potential future upside.
• Employees (including Steven Marso): Those with unvested equity awards had them converted into cash and CVRs, subject to continued service with Pfizer, providing retention incentives.
• Customers/Suppliers: No direct impact detailed in this filing, but the change in ownership may lead to integration with Pfizer's operations.

Next Steps

• Potential future payments to CVR holders upon the achievement of specified milestones.
• Continued service by the reporting person with Pfizer or its subsidiaries to ensure full vesting of converted unvested equity awards.

Key Dates

Keywords

Metsera, Pfizer, Merger, Acquisition, Form 4, Steven Marso, Chief Medical Officer, Common Stock, Restricted Stock Unit, Stock Option, Contingent Value Right, MTSR